Lowering Costs by Improving Biosimilar Uptake Act

Bill 117 HR 7047, also known as the Lowering Costs by Improving Biosimilar Uptake Act, aims to increase the use of biosimilar drugs in the United States in order to lower healthcare costs. Biosimilars are biologic drugs that are highly similar to already approved biologic drugs, but are typically less expensive.

The bill includes provisions to improve education and awareness among healthcare providers and patients about the benefits of biosimilars. It also seeks to address barriers to the adoption of biosimilars, such as patent thickets and anti-competitive practices by drug manufacturers.

Additionally, the bill includes measures to streamline the approval process for biosimilars and increase competition in the biologics market. This is intended to drive down prices and increase access to these important medications for patients. Overall, the Lowering Costs by Improving Biosimilar Uptake Act aims to promote the use of biosimilars as a cost-effective alternative to expensive biologic drugs, ultimately reducing healthcare costs for patients and the healthcare system as a whole.